You can buy or sell MRSN and other stocks, options, and ETFs commission-free!
Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in oncology indications. Its product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC) and XMT-1536, which focuses on ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA. The listed name for MRSN is Mersana Therapeutics, Inc. Common Stock.
52 Week High
52 Week Low
-$0.32 per share
-$0.42 per share